Argenx Se (ARGX) Interest & Investment Income (2016 - 2026)
Argenx Se (ARGX) posted Interest & Investment Income of $44.0 million for Q1 2026, down 1.95% on a QoQ basis from $44.9 million in Q4 2025, and up 18.92% year-over-year from $37.0 million in Q1 2025.
Argenx Se (ARGX) Interest & Investment Income (2016 - 2026) Analysis & Trends
Argenx Se's Interest & Investment Income history runs 11 years deep, the most recent figure standing at $44.0 million for Q1 2026.
- Quarterly Interest & Investment Income rose 18.92% year-over-year to $44.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $170.0 million (up 9.23% YoY) and the FY2025 annual result came in at $163.1 million, up 3.54% from the prior year.
- Interest & Investment Income was $44.0 million for Q1 2026 at Argenx Se, down from $44.9 million in the prior quarter.
- Across five years, Interest & Investment Income topped out at $44.9 million in Q4 2025 and bottomed at $821000.0 in Q1 2022.
- A 5-year average of $29.4 million and a median of $38.4 million in 2025 frame the typical range for Interest & Investment Income.
- Annual changes were most pronounced in 2023 — Interest & Investment Income soared 1920.46% — and 2025, when it dropped 4.87%.
- Argenx Se's Interest & Investment Income stood at $13.9 million in 2022, then surged by 189.46% to $40.3 million in 2023, then fell by 3.01% to $39.1 million in 2024, then increased by 14.78% to $44.9 million in 2025, then fell by 1.95% to $44.0 million in 2026.
- Business Quant data shows ARGX's Interest & Investment Income at $44.0 million in Q1 2026, $44.9 million in Q4 2025, and $42.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 27.66 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 114.80 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -65.80 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 44.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 19.51 Mn |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | 26.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 44.00 Mn |
| Dec 31, 2025 | 44.87 Mn |
| Sep 30, 2025 | 42.70 Mn |
| Jun 30, 2025 | 38.40 Mn |
| Mar 31, 2025 | 37.00 Mn |
| Dec 31, 2024 | 39.10 Mn |
| Sep 30, 2024 | 40.59 Mn |
| Jun 30, 2024 | 38.93 Mn |
| Mar 31, 2024 | 38.90 Mn |
| Dec 31, 2023 | 40.31 Mn |
| Sep 30, 2023 | 30.05 Mn |
| Jun 30, 2023 | 20.44 Mn |
| Mar 31, 2023 | 16.59 Mn |
| Dec 31, 2022 | 13.93 Mn |
| Sep 30, 2022 | 8.01 Mn |
| Jun 30, 2022 | 4.91 Mn |
| Mar 31, 2022 | 821,000.00 |
| Dec 31, 2021 | 1.20 Mn |
| Sep 30, 2021 | 805,000.00 |
| Jun 30, 2021 | 864,000.00 |